Pancreatic Cancer Research Uncovers New Biomarker and Insights into Disease Progression

Strategic Insights -

A team of researchers from Tongji University in Shanghai, People's Republic of China, has made significant discoveries in the field of pancreatic cancer, identifying a new biomarker and shedding light on the regulatory mechanisms underlying the disease. The study, published in The FASEB Journal, aimed to examine the influence of protein arginine methyltransferases (PRMTs) across various cancers and identify potential PRMTs-related prognostic biomarkers.

Key Takeaways:

  • Researchers identified significant PRMTs prognosis-related biomarkers across most cancers using three machine learning algorithms.
  • The study found that PRMT3 might serve as a promising prognostic biomarker for pancreatic cancer.
  • Functional studies demonstrated that the absence of PRMT3 notably inhibited metastasis in pancreatic cancer.
  • Daporinad, dinaciclib, and sepantronium bromide were predicted as potential drugs for the majority of cancer types.
  • The immune regulatory functions of PRMTs in pan-cancer were further examined, highlighting the complexity of PRMTs in cancer progression.
  • Single-cell RNA sequencing data of pancreatic cancer identified ten distinct cell types.
  • The study contributed to a deeper understanding of the regulatory mechanisms of PRMTs in cancer progression.

Statistics:

  • The research used three machine learning algorithms to identify potential PRMTs biomarkers across cancers.
  • The study found that PRMT3 might serve as a biomarker for pancreatic cancer, with a significant impact on metastasis.
  • The absence of PRMT3 inhibited metastasis in pancreatic cancer by __% (statistic not provided in the source).
  • The study examined the immune regulatory functions of PRMTs in pan-cancer, highlighting the complexity of PRMTs in cancer progression.
  • Ten distinct cell types were identified from single-cell RNA sequencing data of pancreatic cancer.

Sources:

  • NewsReport-Staff News Editor. "Studies from Tongji University Provide New Data on Pancreatic Cancer (Interplay of PRMTs and Identification of Biomarkers Through Machine Learning Algorithms in Pan-Cancer, Highlighting PRMT3 as a Biomarker in Pancreatic Cancer)." Cancer Weekly. October 28, 2025; p 4770.
  • Interplay of PRMTs and Identification of Biomarkers Through Machine Learning Algorithms in Pan-Cancer, Highlighting PRMT3 as a Biomarker in Pancreatic Cancer. The FASEB Journal, 2025;39(20).
  • The FASEB Journal. "About Us." Wiley, 2025.
  • Tongji University. "Urologic Cancer Institute." School of Medicine, 2025.
  • Chen, Shiyin, et al. "Interplay of PRMTs and Identification of Biomarkers Through Machine Learning Algorithms in Pan-Cancer, Highlighting PRMT3 as a Biomarker in Pancreatic Cancer." The FASEB Journal, 2025;39(20).